Epigenomic ctDNA Assay Predicts Recurrence in Resected Melanoma
An epigenomic ctDNA assay reading methylation signatures predicts recurrence in resected melanoma, potentially guiding adjuvant therapy and follow-up decisions.
Topic
Ctdna
Topic
Ctdna
MRD-Guided Melanoma Trial Enrolls First Patients With Signatera
First patients enrolled in NCT07504796: Signatera-positive melanoma patients randomized at week six to ipilimumab escalation or c…
Natera Launches Randomized Signatera-Guided Interventional Melanoma Study
Natera will run a randomized interventional melanoma study using its tumor-informed Signatera ctDNA assay to guide treatment, shi…
Immunotherapy Shows Promise for Clearing Residual Melanoma Cells
Cornell Chronicle reports immunotherapy may clear residual melanoma cells persisting after surgery, an early but mechanistically…